MedPath

Verona Pharma, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$2.2B
Website

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

Phase 2
Completed
Conditions
Coronavirus Infection
Covid-19
SARS-CoV-2
Interventions
Drug: Ensifentrine Dose 1
Drug: Placebo pMDI
First Posted Date
2020-08-26
Last Posted Date
2022-09-22
Lead Sponsor
Verona Pharma Inc
Target Recruit Count
45
Registration Number
NCT04527471
Locations
🇺🇸

The University of Alabama at Birmingham, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath